Board Of Directors

John D. Harkey Jr., a Director of the Company since 2006, is Chairman of the Board of Directors and Chief Executive Officer of Consolidated Restaurant Companies, Inc. Mr. Harkey also serves on the Board of Directors and Audit Committees of Leap Wireless International, Inc., Pizza Inn, Loral Space & Communications, Inc., and Energy Transfer Partners, LLC. He also serves on the President's Development Council of Howard Payne University, and on the Executive Board of Circle Ten Council of the Boy Scouts of America. Mr. Harkey is one of the managing directors of Cracken, Harkey & Company, LLC, a private equity firm based in Dallas, Texas. Mr. Harkey obtained a B.B.A. with honors and a J.D. from the University of Texas at Austin, and his MBA from Stanford University School of Business.

Michael V. Novinski, President and Chief Executive Officer of Emisphere, was elected to the Board in May 2008. Previously, Mr. Novinski was President of Organon USA, and Executive Vice President of Operations and Marketing for Organon International. He served on the Board of Directors for Pharmaceutical Research and Manufacturers of America from 2004 through 2008. Mr. Novinski received his B.S. in Biology from Washington and Jefferson College.

Mark H. Rachesky, M.D., a Director of the Company since 2005, is the Founder and President of MHR Fund Management LLC. He was previously managing director and acting chief investment advisor of Icahn Holding Corporation. He serves as a director of Neose Technologies and NovaDel Pharma Inc. Dr. Rachesky is a graduate of Stanford University School of Medicine and Stanford University Business School. He received his B.S. from the University of Pennsylvania.

Tim Rothwell joined the Company's Board of Directors effective November 5, 2009. He previously served as Chairman of Sanofi-aventis U.S. from February 2007 to March 2009, and from September 2004 to February 2007, was President and Chief Executive Officer of the company, overseeing all domestic commercial operations as well as coordination of Industrial Affairs and Research and Development activities. During Mr. Rothwell's career, he has also served as President and Chief Executive Officer of Sanofi-Sythelabo, Inc., President of Pharmacia's Global Prescription Business, worldwide President of Rhone-Poulenc Rorer Pharmaceuticals and President of the company's Global Pharmaceutical Operations, as well as Chief Executive Officer of Sandoz Pharmaceuticals. Mr. Rothwell presently serves on the PhRMA Board of Directors, as well as the Institute of Medicine's Evidence-Based Medicine roundtable, the CEO Roundtable on Cancer, the Healthcare Businesswomen's Association Advisory Board, the Board of Trustees for the Somerset Medical Center Foundation, the Board of Trustees for the HealthCare Institute of New Jersey and the Board of Visitors for Seton Hall Law School. He is also a Trustee of the Corporate Council for America's Children at the Children's Health Fund. Mr. Rothwell holds a Bachelor of Arts from Drew University and earned his J.D. from Seton Hall University.

Michael Weiser, M.D., Ph.D., a Director of the Company since 2005, is currently founder and co-chairman of Actin Biomed, a New York based healthcare investment firm advancing the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Biomed, Dr. Weiser was the Director of Research at Paramount BioCapital where he was responsible for the scientific, medical and financial evaluation of biomedical technologies and pharmaceutical products under consideration for development. Dr. Weiser completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College and received his M.D. from New York University School of Medicine. He performed his post-graduate medical training in the Department of Obstetrics and Gynecology at New York University Medical Center. Dr. Weiser also completed a Postdoctoral Fellowship in the Department of Physiology and Neuroscience at New York University School of Medicine and received his B.A. in Psychology from University of Vermont. Dr. Weiser currently serves on the board of directors of Manhattan Pharmaceuticals, Inc, Chelsea Therapeutics International, Ltd., Emisphere, Hana Biosciences, Inc., Ziopharm Oncology, Inc. and Vioquest Pharmaceuticals, Inc. as well as several privately held companies..